But the company counted 21 M A deals , valued at 1 . 59 billion , involving U . S . pharma , medical and biotech companies moving to the U . K . this year , and another five deals valued at 184 billion involving U . S . companies from that sector heading to Ireland , which has an even more favorable corporate tax regime . That compares with the 26 deals valued at 5 . 54 billion involving U . S . drug and medical companies moving to the U . K . in 2014 , and the seven deals valued at 46 . 9 billion that brought them to Ireland .
